Table 1.
Ongoing clinical trials targeting molecular pathways involving patients with calcific aortic valve disease (CAVD).
| Study Name and NCT Identifier |
Principal Investigator and Institution |
Pharmacological Target and Treatment Arms |
Recruitment Status |
|---|---|---|---|
| A study evaluating the effects of Ataciguat (HMR1766) on aortic valve calcification (CAVS) NCT02481258 | Jordan D Miller; Mayo Clinic, Rochester, Minnesota, United States | Nitric oxide-independent soluble guanylate cyclase activator Ataciguat (HMR1766) 200 mg daily for 12 months vs. placebo |
Completed, results awaited |
| Effect of PCSK9 inhibitors on calcific aortic valve disease (EPISODE) NCT04968509 | Zhijian Wang; Beijing Anzhen Hospital, China | PCSK9 inhibitors (lipid lowering) 140 mg PCSK9 inhibitors (140 mg Evolocumab or Alirocumab subcutaneously every two weeks and conventional lipid lowering therapy (Atorvastatin 40–80 mg or Rosuvastatin 20–40 mg or Atorvastatin 20 mg+ Ezetimibe 10 mg or Rosuvastatin 10 mg+ Ezetimibe 10 mg vs. Conventional lipid-lowering therapy (Atorvastatin 40–80 mg or Rosuvastatin 20–40 mg or Atorvastatin 20 mg+ Ezetimibe 10 mg or Rosuvastatin 10 mg+ Ezetimibe) |
Recruiting |
| A Study to evaluate the efficacy and safety of DA-1229 (Evogliptin) in patients with calcific aortic valve disease with mild to moderate stenosis (EVOID-AS) NCT05143177 | REDNVIA Co., Ltd. | DA-1229 anti-diabetic Three arm study where patients will receive one of the three treatments orally once daily for period of 104 weeks; DA-1229 5 mg once vs. GroupDA-1229 10 mg vs. Placebo |
Not yet recruiting |
| Colchicine and Inflammation in Aortic Stenosis (CHIANTI) NCT05162742 |
Radboud University Medical Centre | Colchicine vs. placebo | Not yet recruiting |
| Slower progress of calcification with Vitamin K2 (SLOW) NCT04429035 | First Department of Cardiology, University of Athens Athens, Attiki, Greece Hippokration Hospital 1st Department of Cardiology, National and Kapodistrian University of Athens, Medical School Athens, Attiki, Greece |
Dietary Supplement: Vitamin K2 vs. Dietary Supplement: Placebo | Recruiting |